Fibromyalgia in Pregnancy: Neuro-Endocrine Fluctuations Provide Insight into Pathophysiology and Neuromodulation...

Area of Science:

• Neuroscience
• Endocrinology
• Immunology

Background:

• Fibromyalgia (FM) is a chronic pain disorder with complex symptoms including fatigue, sleep disruption, and cognitive difficulties.
• FM disproportionately affects females, with symptom severity linked to hormonal fluctuations and immune system changes.
• Pregnancy, particularly the third trimester and postpartum period, is associated with aggravated FM symptoms in many women.

Purpose of the Study:

• To explore the neuro-endocrine interactions involving progesterone, allopregnanolone, and cortisol during pregnancy in relation to FM pathogenesis.
• To propose a hypothesis linking these neuro-endocrine changes to a previously suggested model of FM involving GABAergic system weakening in thalamocortical pathways.
• To introduce transcranial direct current stimulation (tDCS) as a potential non-invasive, sex-specific therapeutic intervention for FM.

Main Methods:

• This is a perspective paper, not an experimental study.
• The authors review existing literature on FM, neuro-endocrinology during pregnancy, and GABAergic mechanisms.
• The paper proposes a theoretical model and a potential treatment approach based on current evidence.

Main Results:

• The paper hypothesizes that neuro-endocrine shifts during pregnancy, specifically involving progesterone, allopregnanolone, and cortisol, may exacerbate FM symptoms.
• This hypothesis aligns with a proposed model of FM pathogenesis involving GABAergic system dysfunction.
• Transcranial direct current stimulation (tDCS) is suggested as a potential treatment that may modulate these pathways in a sex-specific manner.

Conclusions:

• Neuro-endocrine interactions during pregnancy may play a significant role in modulating fibromyalgia symptoms.
• The proposed model suggests GABAergic system weakening as a key factor in FM pathogenesis.
• Transcranial direct current stimulation (tDCS) warrants further investigation as a potential sex-specific treatment for fibromyalgia, particularly in the context of pregnancy-related symptom exacerbation.